The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

The cerebrospinal fluid (CSF) biomarkers amyloid β (Aβ)-42, total-tau (T-tau), and phosphorylated-tau (P-tau) demonstrate good diagnostic accuracy for Alzheimer’s disease
(AD). However, there are large variations in biomarker measurements between studies, and
between and within laboratories. The Alzheimer’s Association has initiated a global quality
control program to estimate and monitor variability of measurements, quantify batch-to-batch
assay variations, and identify sources of variability. In this article, we present the results from the
first two rounds of the program.